Jo Evans.
@oncolojo.bsky.social
Consultant medical oncologist @ Imperial College Healthcare NHS Trust (Thoracic Oncology, Acute Oncology), Honorary Senior Clinical Lecturer @ Imperial College. Mum to Mr11. Perpetually tired!
No, but we MUST fund it adequately. We are seeing many more patients and for longer without any additional resource. Burnout is real
April 22, 2025 at 4:53 PM
No, but we MUST fund it adequately. We are seeing many more patients and for longer without any additional resource. Burnout is real
Not sure whether to laugh or cry at this…
It’s definitely a little cry in the corner
It’s definitely a little cry in the corner
March 19, 2025 at 3:08 PM
Not sure whether to laugh or cry at this…
It’s definitely a little cry in the corner
It’s definitely a little cry in the corner
Completely agree! We have some exceptional clinical nurse specialist with a host of different skills and strengths to add positivity to the patient pathway! Here’s to all our cancer CNS team! You are worth your weight in anti-PDL1/PD1 antibodies (ie > than gold)
March 14, 2025 at 9:04 PM
Completely agree! We have some exceptional clinical nurse specialist with a host of different skills and strengths to add positivity to the patient pathway! Here’s to all our cancer CNS team! You are worth your weight in anti-PDL1/PD1 antibodies (ie > than gold)
I’m just updating some teaching slides for next week and it always hits me as almost new information when I remind myself many of the stats in Paramount were descriptive!
March 7, 2025 at 12:34 PM
I’m just updating some teaching slides for next week and it always hits me as almost new information when I remind myself many of the stats in Paramount were descriptive!
Caution with extrapolating data from completely different cohorts…. I personally hate pemetrexed (for renal issues and fatigue) and wonder what this data would look like in a predominantly Caucasian population? Before asking if pemetrexed maintenance has a role in the IO era…
March 7, 2025 at 12:32 PM
Caution with extrapolating data from completely different cohorts…. I personally hate pemetrexed (for renal issues and fatigue) and wonder what this data would look like in a predominantly Caucasian population? Before asking if pemetrexed maintenance has a role in the IO era…